Lupin opens inhalation research centre in US
The new centre in Florida will to focus on the R&D of inhalation products for the treatment of asthma, chronic obstructive pulmonary diseases and other lung diseases
“With the talent and resources this state provides, our Coral Springs expansion will further strengthen our ability to bring quality, affordable pharmaceuticals to patients in the United States and other key markets globally. The new inhalation research and development facility is a significant step forward in our journey to emerge as a global specialty pharmaceutical player,” said Vinita Gupta, CEO, Lupin Limited.